Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rita Frangiamore

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Immunotargets and Therapy|December 28, 2020
Complement Inhibition for the Treatment of Myasthenia GravisRenato Mantegazza, Fiammetta Vanoli, Rita Frangiamore, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 6, 2021
Iatrogenic Kaposi's sarcoma in myasthenia gravis: learnings from two case reportsRita Frangiamore, Riccardo Giossi, Fiammetta Vanoli, et al.
Neuroepidemiology|February 26, 2020
Employment in Myasthenia Gravis: A Systematic Literature Review and Meta-AnalysisErika Guastafierro, Irene Tramacere, Claudia Toppo, et al.
Frontiers in Immunology|March 27, 2020
miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of CorticosteroidsFederica Bortone, Letizia Scandiffio, Stefania Marcuzzo, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 25, 2025
Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experienceCarlo Antozzi, Rita Frangiamore, Elena Rinaldi, et al.
SAGE Open Medicine|December 22, 2018
Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover studySilvia Bonanno, Maria Barbara Pasanisi, Rita Frangiamore, et al.
Clinical Immunology (Orlando, Fla.)|October 11, 2016
Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapiesChiara Cordiglieri, Fulvio Baggi, Pia Bernasconi, et al.
Muscle & Nerve|May 5, 2023
Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scoresSarah Dewilde, M F Janssen, Nafthali H Tollenaar, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 20, 2026
Disease changes and cost analysis of myasthenia gravis: a 10 years retrospective study from a reference center in ItalyRenato Mantegazza, Carlo Antozzi, Fulvio Baggi, et al.
Biomedicines|June 24, 2022
Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement TherapyNicola Iacomino, Fiammetta Vanoli, Rita Frangiamore, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Immunotargets and Therapy|December 28, 2020
Complement Inhibition for the Treatment of Myasthenia GravisRenato Mantegazza, Fiammetta Vanoli, Rita Frangiamore, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 6, 2021
Iatrogenic Kaposi's sarcoma in myasthenia gravis: learnings from two case reportsRita Frangiamore, Riccardo Giossi, Fiammetta Vanoli, et al.
Neuroepidemiology|February 26, 2020
Employment in Myasthenia Gravis: A Systematic Literature Review and Meta-AnalysisErika Guastafierro, Irene Tramacere, Claudia Toppo, et al.
Frontiers in Immunology|March 27, 2020
miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of CorticosteroidsFederica Bortone, Letizia Scandiffio, Stefania Marcuzzo, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 25, 2025
Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experienceCarlo Antozzi, Rita Frangiamore, Elena Rinaldi, et al.
SAGE Open Medicine|December 22, 2018
Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover studySilvia Bonanno, Maria Barbara Pasanisi, Rita Frangiamore, et al.
Clinical Immunology (Orlando, Fla.)|October 11, 2016
Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapiesChiara Cordiglieri, Fulvio Baggi, Pia Bernasconi, et al.
Muscle & Nerve|May 5, 2023
Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scoresSarah Dewilde, M F Janssen, Nafthali H Tollenaar, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 20, 2026
Disease changes and cost analysis of myasthenia gravis: a 10 years retrospective study from a reference center in ItalyRenato Mantegazza, Carlo Antozzi, Fulvio Baggi, et al.
Biomedicines|June 24, 2022
Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement TherapyNicola Iacomino, Fiammetta Vanoli, Rita Frangiamore, et al.
Pageof 3